CompletedPhase 2NCT00003846
Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- H. Stacy Nicholson, MD, MPHOHSU Knight Cancer Institute
- Intervention
- filgrastim(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 3-21 years · All sexes
- Timeline
- 1999 – 2007
Study locations (13)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's Hospital of Denver, Denver, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
- NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States
- Children's Hospital of Columbus, Columbus, Ohio, United States
- Oregon Cancer Center at Oregon Health Sciences University, Portland, Oregon, United States
- University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003846 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University